But there’s a powerful fundamental story happening with Boston Scientific. Also, EPS is estimated to ramp higher this year by +13.8%. Now it makes sense why the stock has been powering to new ...

Expert Rev Gastroenterol Hepatol. 2012;6(1):105-114. When double-stent placement (duodenal and biliary) is considered, biliary stent placement can be performed either preceding or following ...

Boston Scientific’s BSX robust expansion of operations across different geographies outside the United States is poised to help it grow in the upcoming quarters. The company’s ...

Boston Scientific closes the year at historic highs, with investors refusing to liquidate even at these levels. The smooth upward movement of the stock indicates the quality of its investor base.

The exciting scientific developments present threats as well as opportunities. Dozens of leading researchers including two Nobel Prize winners have warned of the potentially catastrophic impact of ...